Roche scraps sec­ond mid-stage schiz­o­phre­nia tri­al in as many years

Roche has ter­mi­nat­ed the sec­ond of two Phase II stud­ies test­ing its in­ves­ti­ga­tion­al schiz­o­phre­nia drug ralmi­taront, per an up­date to the fed­er­al clin­i­cal tri­als data­base.

The Swiss Big Phar­ma end­ed the first one for pos­i­tive symp­toms of schiz­o­phre­nia last year and now has end­ed the oth­er study, for neg­a­tive symp­toms, af­ter an in­ter­im analy­sis “in­di­cat­ed that ralmi­taront was un­like­ly to meet its pri­ma­ry end­point.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER